Literature DB >> 10843047

The Streptococcus anginosus species comprises five 16S rRNA ribogroups with different phenotypic characteristics and clinical relevance.

J A Jacobs, C S Schot, L M Schouls.   

Abstract

A collection of 267 consecutively isolated Streptococcus anginosus strains was screened for the prevalence of previously described 'motile' strains by hybridization with oligonucleotide probes in a reverse line blot assay. The motile strains represented 101 (37.8%) of the S. anginosus strains. The vast majority of these strains fermented mannitol and raffinose, whereas most other S. anginosus strains did not (P<0.001). Most (83/101) of the motile strains were recovered from the urogenital tract (including five strains from neonatal surveillance cultures) and only a minority (36) of them were associated with infection-related samples (P<0.001). Strains that hybridized with the same oligonucleotide probes as the type strain S. anginosus ATCC 33397T (= NCTC 10713T) were designated ATCC-like strains. They accounted for 74 (27.7%) of the strains examined, were commonly distributed among the different body parts and were significantly more associated with infection-related samples. Three other hybridization patterns were recognized in the reverse line blot assay, ribogroup I (n = 51), ribogroup II (n = 21) and ribogroup III (n = 19). Ribogroup II strains were significantly more frequently recovered from the abdominal cavity and were associated with infection-related samples. Ribogroup I included the majority of the S. anginosus strains that carried Lancefield group C. Comparison of the nearly complete 16S rRNA sequence of two representative strains of each ribogroup revealed that all five ribogroups were closely related (>97% sequence similarities), and that most sequence divergences between the ribogroups occurred in the 1024-1064 bp region of the 16S rRNA gene. The present data confirm the heterogeneity within the S. anginosus species.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10843047     DOI: 10.1099/00207713-50-3-1073

Source DB:  PubMed          Journal:  Int J Syst Evol Microbiol        ISSN: 1466-5026            Impact factor:   2.747


  7 in total

1.  Prevalence of macrolide resistance genes in clinical isolates of the Streptococcus anginosus ("S. milleri") group.

Authors:  J A Jacobs; G J van Baar; N H London; J H Tjhie; L M Schouls; E E Stobberingh
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

2.  Horizontal transfer of segments of the 16S rRNA genes between species of the Streptococcus anginosus group.

Authors:  Leo M Schouls; Corrie S Schot; Jan A Jacobs
Journal:  J Bacteriol       Date:  2003-12       Impact factor: 3.490

3.  Species-Specific Identification of Streptococcus based on DNA Marker in 16S-23S rDNA Internal Transcribed Spacer.

Authors:  Jia Yu; Ting Zhou; Baojie Zhu; Yuxi Wei; Xuerui Li; Yin Liu
Journal:  Curr Microbiol       Date:  2020-04-06       Impact factor: 2.188

4.  Identification of 43 Streptococcus species by pyrosequencing analysis of the rnpB gene.

Authors:  Asa Innings; Margareta Krabbe; Måns Ullberg; Björn Herrmann
Journal:  J Clin Microbiol       Date:  2005-12       Impact factor: 5.948

5.  Genotyping by amplified fragment length polymorphism analysis reveals persistence and recurrence of infection with Streptococcus anginosus group organisms.

Authors:  Jan A Jacobs; Jeroen H T Tjhie; Monique G J Smeets; Corrie S Schot; Leo M Schouls
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

Review 6.  What happened to the streptococci: overview of taxonomic and nomenclature changes.

Authors:  Richard Facklam
Journal:  Clin Microbiol Rev       Date:  2002-10       Impact factor: 26.132

7.  Identification of clinically relevant nonhemolytic Streptococci on the basis of sequence analysis of 16S-23S intergenic spacer region and partial gdh gene.

Authors:  Xiaohui Chen Nielsen; Ulrik Stenz Justesen; Rimtas Dargis; Michael Kemp; Jens Jørgen Christensen
Journal:  J Clin Microbiol       Date:  2009-02-04       Impact factor: 5.948

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.